Urovant Sciences and Genmab reported disappointing clinical trial announcements.

Following a mid-stage flop, Ironwood and AbbVie discontinued the development of an experimental drug aimed at the treatment of abdominal pain associated with irritable bowel syndrome with diarrhea (IBS-D).

Boston Pharmaceuticals licenses a slew of compounds from GlaxoSmithKline and Novartis in two separate deals.